Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

Malcolm A. Smith, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, John M. Maris, Stephen T. Keir, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, Janine Arts, Tarig Bashir, Michel Janicot, Raushan T. Kurmasheva, Peter J. Houghton

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

Original languageEnglish (US)
Pages (from-to)329-332
Number of pages4
JournalPediatric Blood and Cancer
Volume59
Issue number2
DOIs
StatePublished - Aug 2012

Fingerprint

Heterografts
Pediatrics
Cell Line
Neoplasms
Apoptosis
JNJ 26854165

Keywords

  • Developmental therapeutics
  • JNJ-26854165
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., ... Houghton, P. J. (2012). Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 59(2), 329-332. https://doi.org/10.1002/pbc.23319

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. / Smith, Malcolm A.; Gorlick, Richard; Kolb, E. Anders; Lock, Richard; Carol, Hernan; Maris, John M.; Keir, Stephen T.; Morton, Christopher L.; Reynolds, C. Patrick; Kang, Min H.; Arts, Janine; Bashir, Tarig; Janicot, Michel; Kurmasheva, Raushan T.; Houghton, Peter J.

In: Pediatric Blood and Cancer, Vol. 59, No. 2, 08.2012, p. 329-332.

Research output: Contribution to journalArticle

Smith, MA, Gorlick, R, Kolb, EA, Lock, R, Carol, H, Maris, JM, Keir, ST, Morton, CL, Reynolds, CP, Kang, MH, Arts, J, Bashir, T, Janicot, M, Kurmasheva, RT & Houghton, PJ 2012, 'Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 59, no. 2, pp. 329-332. https://doi.org/10.1002/pbc.23319
Smith, Malcolm A. ; Gorlick, Richard ; Kolb, E. Anders ; Lock, Richard ; Carol, Hernan ; Maris, John M. ; Keir, Stephen T. ; Morton, Christopher L. ; Reynolds, C. Patrick ; Kang, Min H. ; Arts, Janine ; Bashir, Tarig ; Janicot, Michel ; Kurmasheva, Raushan T. ; Houghton, Peter J. / Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 2. pp. 329-332.
@article{1525989f5cd5436d8ea74e3721b510ff,
title = "Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program",
abstract = "JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.",
keywords = "Developmental therapeutics, JNJ-26854165, Preclinical testing",
author = "Smith, {Malcolm A.} and Richard Gorlick and Kolb, {E. Anders} and Richard Lock and Hernan Carol and Maris, {John M.} and Keir, {Stephen T.} and Morton, {Christopher L.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Janine Arts and Tarig Bashir and Michel Janicot and Kurmasheva, {Raushan T.} and Houghton, {Peter J.}",
year = "2012",
month = "8",
doi = "10.1002/pbc.23319",
language = "English (US)",
volume = "59",
pages = "329--332",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program

AU - Smith, Malcolm A.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Lock, Richard

AU - Carol, Hernan

AU - Maris, John M.

AU - Keir, Stephen T.

AU - Morton, Christopher L.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Arts, Janine

AU - Bashir, Tarig

AU - Janicot, Michel

AU - Kurmasheva, Raushan T.

AU - Houghton, Peter J.

PY - 2012/8

Y1 - 2012/8

N2 - JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

AB - JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC 50 (0.85μM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.

KW - Developmental therapeutics

KW - JNJ-26854165

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84862269393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862269393&partnerID=8YFLogxK

U2 - 10.1002/pbc.23319

DO - 10.1002/pbc.23319

M3 - Article

C2 - 21922647

AN - SCOPUS:84862269393

VL - 59

SP - 329

EP - 332

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -